Joshua M Bauml1,2, Ravi Vinnakota3, Yeun-Hee Anna Park3,4, Susan E Bates3,4, Tito Fojo3,4, Charu Aggarwal2, Sewanti Limaye3, Nevena Damjanov1,2, Jessica Di Stefano1, Christine Ciunci2, Eric M Genden5, Juan P Wisnivesky6, Rocco Ferrandino6, Ronac Mamtani2, Corey J Langer2, Roger B Cohen2, Keith Sigel3,6,7. 1. Department of Medicine, Division of Hematology/Oncology, Michael J. Crescenz VA Medical Center, Philadelphia, PA. 2. Department of Medicine, Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. 3. Department of Medicine, Division of Hematology/Oncology, James J. Peters VA Medical Center, Bronx, NY. 4. Department of Medicine, Division of Hematology/Oncology, The College of Physicians and Surgeons at Columbia University, New York, NY. 5. Department of Otolaryngology, The Mount Sinai School of Medicine, New York, NY. 6. Department of Medicine, Division of General Internal Medicine, The Mount Sinai School of Medicine, New York, NY. 7. Department of Medicine, Division of Infectious Disease, The Mount Sinai School of Medicine, New York, NY.
Abstract
BACKGROUND: Concurrent chemoradiotherapy is an established component of the nonoperative management of locally advanced head and neck squamous cell carcinoma (HNSCC), but the standard dose of 100 mg/m2 cisplatin every 3 weeks is associated with clinically significant toxicity. Interest in a more tolerable regimen has led to the widespread use of weekly lower dose cisplatin, but few randomized trials have compared these approaches. METHODS: We examined outcomes of patients with stage III-IVb HNSCC treated with definitive intent chemoradiotherapy using either high-dose cisplatin (HDC) or low-dose cisplatin (LDC), using population-based Veterans Affairs data. In an intent-to-treat analysis, patients were assigned to the HDC vs LDC group according to the dose of their first cycle. Variables potentially influencing treatment decisions including cancer site, stage, smoking/alcohol use, and comorbidities were used to generate propensity scores (PS) for the use of HDC. We compared overall survival (OS) by treatment group using Cox regression, adjusting for PS. We then determined the risk of toxicities using PS-adjusted logistic regression. RESULTS: A total of 2901 patients were included in the analysis; 2200 received HDC (mean initial dose 100 mg/m2). The mean initial dose of LDC was 40 mg/m2. After PS adjustment, HDC was not associated with improved OS over LDC (hazard ratio = 0.94, 95% confidence interval = 0.80 to 1.04). Adjusting for PS, HDC was associated with an increased risk of acute kidney injury, neutropenia, dehydration/electrolyte disturbance, and hearing loss. CONCLUSION: In this large, population-based study of US military veterans, LDC was associated with similar survival to HDC in the nonoperative definitive management of locally advanced HNSCC of the oral cavity, oropharynx, and hypopharynx/larynx. HDC was associated with statistically significantly more toxicity than LDC. Adoption of LDC may reduce toxicity burden while maintaining OS. Published by Oxford University Press 2018.
BACKGROUND: Concurrent chemoradiotherapy is an established component of the nonoperative management of locally advanced head and neck squamous cell carcinoma (HNSCC), but the standard dose of 100 mg/m2 cisplatin every 3 weeks is associated with clinically significant toxicity. Interest in a more tolerable regimen has led to the widespread use of weekly lower dose cisplatin, but few randomized trials have compared these approaches. METHODS: We examined outcomes of patients with stage III-IVb HNSCC treated with definitive intent chemoradiotherapy using either high-dose cisplatin (HDC) or low-dose cisplatin (LDC), using population-based Veterans Affairs data. In an intent-to-treat analysis, patients were assigned to the HDC vs LDC group according to the dose of their first cycle. Variables potentially influencing treatment decisions including cancer site, stage, smoking/alcohol use, and comorbidities were used to generate propensity scores (PS) for the use of HDC. We compared overall survival (OS) by treatment group using Cox regression, adjusting for PS. We then determined the risk of toxicities using PS-adjusted logistic regression. RESULTS: A total of 2901 patients were included in the analysis; 2200 received HDC (mean initial dose 100 mg/m2). The mean initial dose of LDC was 40 mg/m2. After PS adjustment, HDC was not associated with improved OS over LDC (hazard ratio = 0.94, 95% confidence interval = 0.80 to 1.04). Adjusting for PS, HDC was associated with an increased risk of acute kidney injury, neutropenia, dehydration/electrolyte disturbance, and hearing loss. CONCLUSION: In this large, population-based study of US military veterans, LDC was associated with similar survival to HDC in the nonoperative definitive management of locally advanced HNSCC of the oral cavity, oropharynx, and hypopharynx/larynx. HDC was associated with statistically significantly more toxicity than LDC. Adoption of LDC may reduce toxicity burden while maintaining OS. Published by Oxford University Press 2018.
Authors: D G Pfister; K Ang; B Brockstein; A D Colevas; J Ellenhorn; H Goepfert; W L Hicks; W K Hong; M S Kies; W Lydiatt; T McCaffrey; B B Mittal; J A Ridge; D E Schuller; J P Shah; S Spencer; A Trotti; S Urba; E A Weymuller; R H Wheeler; G T Wolf Journal: Oncology (Williston Park) Date: 2000-11 Impact factor: 2.990
Authors: B Biedermann; C Landmann; R Kann; J Passweg; M Solèr; A Lohri; C Rochlitz; R Herrmann; M Pless Journal: Radiother Oncol Date: 2000-08 Impact factor: 6.280
Authors: A T C Chan; P M L Teo; R K Ngan; T W Leung; W H Lau; B Zee; S F Leung; F Y Cheung; W Yeo; H H Yiu; K H Yu; K W Chiu; D T Chan; T Mok; K T Yuen; F Mo; M Lai; W H Kwan; P Choi; P J Johnson Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Arnold L Potosky; Joan L Warren; Elyn R Riedel; Carrie N Klabunde; Craig C Earle; Colin B Begg Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Beth A Virnig; Joan L Warren; Gregory S Cooper; Carrie N Klabunde; Nicola Schussler; Jean Freeman Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: David J Adelstein; Yi Li; George L Adams; Henry Wagner; Julie A Kish; John F Ensley; David E Schuller; Arlene A Forastiere Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544
Authors: Teresa F Brunner; Florian A Probst; Matthias Troeltzsch; Sabina Schwenk-Zieger; Julia L Zimmermann; Gregor Morfill; Sven Becker; Ulrich Harréus; Christian Welz Journal: Head Face Med Date: 2022-06-29 Impact factor: 2.246
Authors: Giacomo Miserocchi; Chiara Spadazzi; Sebastiano Calpona; Francesco De Rosa; Alice Usai; Alessandro De Vita; Chiara Liverani; Claudia Cocchi; Silvia Vanni; Chiara Calabrese; Massimo Bassi; Giovanni De Luca; Giuseppe Meccariello; Toni Ibrahim; Marco Schiavone; Laura Mercatali Journal: J Pers Med Date: 2022-05-24
Authors: Jung Julie Kang; Vatche Tchekmedyian; Nader Mohammed; Alisa Rybkin; Sarin Kitpanit; Ming Fan; Huili Wang; Stephanie M Lobaugh; Zhigang Zhang; Anna Lee; Linda Chen; Yao Yu; Kaveh Zakeri; Daphna Y Gelblum; Nadeem Riaz; Sean M McBride; C Jillian Tsai; Marc A Cohen; Jennifer R Cracchiolo; Luc G Morris; Bhuvanesh Singh; Snehal Patel; Ian Ganly; Jay O Boyle; Richard J Wong; Juliana Eng; Wanqing Iris Zhi; Kenneth Ng; Alan L Ho; Lara A Dunn; Loren Michel; James V Fetten; David G Pfister; Nancy Y Lee; Eric J Sherman Journal: Int J Cancer Date: 2021-02-27 Impact factor: 7.316
Authors: Gregory S Weinstein; Roger Cohen; Alexander Lin; Bert W O'Malley; John Lukens; Samuel Swisher-McClure; Rabie M Shanti; Jason G Newman; Harman S Parhar; Kendall Tasche; Robert M Brody; Ara Chalian; Steven Cannady; James N Palmer; Nithin D Adappa; Michael A Kohanski; Joshua Bauml; Charu Aggarwal; Kathleen Montone; Virginia Livolsi; Zubair W Baloch; Jalal B Jalaly; Kumarasen Cooper; Karthik Rajasekaran; Laurie Loevner; Christopher Rassekh Journal: Head Neck Date: 2020-06-25 Impact factor: 3.147
Authors: Hye Ri Han; Sung Jun Ma; Gregory M Hermann; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni A Kuriakose; Michael R Markiewicz; Jon M Chan; Mary E Platek; Andrew D Ray; Fangyi Gu; Wesley L Hicks; Anurag K Singh Journal: Ann Transl Med Date: 2021-05
Authors: Arslan Babar; Neil M Woody; Ahmed I Ghanem; Jillian Tsai; Neal E Dunlap; Matthew Schymick; Howard Y Liu; Brian B Burkey; Eric D Lamarre; Jamie A Ku; Joseph Scharpf; Brandon L Prendes; Nikhil P Joshi; Jimmy J Caudell; Farzan Siddiqui; Sandro V Porceddu; Nancy Lee; Larisa Schwartzman; Shlomo A Koyfman; David J Adelstein; Jessica L Geiger Journal: Curr Oncol Date: 2021-06-30 Impact factor: 3.677
Authors: Ryan T Hughes; Mercedes Porosnicu; Beverly J Levine; Thomas W Lycan; Rachel F Shenker; Bart A Frizzell; Kathryn M Greven Journal: J Med Imaging Radiat Oncol Date: 2021-07-26 Impact factor: 1.667